Plasma 8-hydroxy-2′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

Article type: Research Article

Authors: Biglan, K.M. | Dorsey, E.R.^; | Evans, R.V.V. | Ross, C.A. | Hersch, S. | Shoulson, I.^; | Matson, W. | Kieburtz, K. | for the Huntington Study Group Pre2CARE Investigators

Affiliations: Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA | Department of Neurology, Johns Hopkins University, Baltimore, MD, USA | Departments of Psychiatry, Neurology, Neuroscience and Pharmacology, Johns Hopkins University, Baltimore, MD, USA | Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA | Department of Neurology, Georgetown University, Washington, D.C., USA | Boston University School of Medicine, Boston, MA, USA

Note: [] Correspondence to: Kevin M. Biglan, MD, MPH, Associate Professor, Department of Neurology, University of Rochester, 1351 Mt. Hope Ave, Suite 223, Rochester, NY 14620, USA. Tel.: +1 585 275 2427; Fax: +1 585 276 1870; E-mail: [email protected]

Keywords: Huntington disease, coenzyme Q10, 8OHdG, oxidative injury

DOI: 10.3233/JHD-2012-120007

Journal: Journal of Huntington's Disease, vol. 1, no. 1, pp. 65-69, 2012